Work

Abstract A003: COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in patients with metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC), and colorectal cancer (CRC) with activating KRAS mutations

Year: 2023

Type: conference-abstract

Source: Molecular Cancer Research

DOI: 10.1158/1557-3125.ras23-a003

Authors: Stacey A. Cohen, Christos Fountzilas, David Sommerhalder, Sandip Patel, Ai Benson, Kai He, Apar Ganti, Alex Spira, Bhagyashree (Kelshikar) Yadav, Alex Cacovean, Steve Morris, Tom Butler, David Hong

Institutions: Fred Hutch Cancer Center, Roswell Park Comprehensive Cancer Center, University of California San Diego, Northwestern Medicine, The Ohio State University, University of Nebraska at Omaha, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4367603510

Cites:

Cited by:

Related to: 10